Raffles Medical Group said full-year profit after tax and minority interests climbed 13.4% to S$70.6 million for the 12 months ended 31 Dec 2025, lifted by firmer contributions from its hospital and insurance operations as well as fair-value gains on investment properties. Net profit for the second half alone advanced 21.7% year-on-year to S$38.5 million.
Diluted earnings per share rose 14.1% to 3.81 Singapore cents. The board proposed a final cash dividend of 3.0 cents a share—about 84% of sustainable PATMI—subject to shareholder approval at the forthcoming annual general meeting.
Group revenue in FY2025 inched up 1.8% year-on-year to S$765.3 million. Hospital Services led growth with turnover up 3.5% to S$357.8 million and pre-tax profit rising 15.3% to S$41.1 million, aided by higher patient volumes, larger average bills and cost efficiencies across Singapore and China. Healthcare Services booked revenue of S$285.9 million, broadly stable from the previous year, while Raffles Health Insurance lifted revenue 4.1% to S$185.2 million and improved profitability by 50.6% on tighter claims management and cost control.
Although top-line expansion remained modest, the group cited disciplined operational execution, a healthier case mix and ongoing efficiency drives for the uplift in margins. Cash and cash equivalents stood at S$310.8 million at year-end, supported by S$101.3 million in operating cash flow.
Looking ahead, Raffles Medical is positioning for demographic shifts in Singapore and China, with plans to broaden elder-care and preventive health services. Scheduled for opening in the first quarter of 2026, the Raffles Healthy Longevity Centre will offer physician-led, multidisciplinary programmes focused on preventive care and ageing well. The group also intends to accelerate adoption of artificial-intelligence tools to enhance clinical and operational efficiency, and will launch a new insurance rider to address recent regulatory changes on co-payment requirements in Singapore.
Executive chairman Dr Loo Choon Yong said the 50th-anniversary year and the stronger 2025 performance underscore the group’s solid foundations and the trust it has built with patients. He noted that Raffles Medical is entering its “next phase of growth” by expanding service depth and geographic reach across its 14 Asian cities while maintaining a disciplined approach to capital allocation. The board expects the company to stay profitable in FY2026, barring unforeseen circumstances.